CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Portugal.
Cell Calcium. 2012 Feb;51(2):95-106. doi: 10.1016/j.ceca.2011.11.008. Epub 2011 Dec 15.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to debilitating cognitive deficits. Recent evidence demonstrates that glutamate receptors are dysregulated by amyloid beta peptide (Aβ) oligomers, resulting in disruption of glutamatergic synaptic transmission which parallels early cognitive deficits. Although it is well accepted that neuronal death in AD is related to disturbed intracellular Ca(2+) (Ca(2+)(i)) homeostasis, little is known about the contribution of NMDARs containing GluN2A or GluN2B subunits on Aβ-induced Ca(2+)(i) rise and neuronal dysfunction. Thus, the main goal of this work was to evaluate the role of NMDAR subunits in dysregulation of Ca(2+)(i) homeostasis induced by Aβ 1-42 preparation containing both oligomers (in higher percentage) and monomers in rat cerebral cortical neurons. The involvement of NMDARs was evaluated by pharmacological inhibition with MK-801 or the selective GluN2A and GLUN2B subunit antagonists NVP-AAM077 and ifenprodil, respectively. We show that Aβ, like NMDA, increase Ca(2+)(i) levels mainly through activation of NMDARs containing GluN2B subunits. Conversely, GluN2A-NMDARs antagonism potentiates Ca(2+)(i) rise induced by a high concentration of Aβ (1μM), suggesting that GluN2A and GluN2B subunits have opposite roles in regulating Ca(2+)(i) homeostasis. Moreover, Aβ modulate NMDA-induced responses and vice versa. Indeed, pre-exposure to Aβ (1μM) decrease NMDA-evoked Ca(2+)(I) rise and pre-exposure to NMDA decrease Aβ response. Interestingly, simultaneous addition of Aβ and NMDA potentiate Ca(2+)(I) levels, this effect being regulated by GluN2A and GluN2B subunits in opposite manners. This study contributes to the understanding of the molecular basis of early AD pathogenesis, by exploring the role of GluN2A and GluN2B subunits in the mechanism of Aβ toxicity in AD.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,可导致衰弱性认知障碍。最近的证据表明,谷氨酸受体被淀粉样β肽(Aβ)寡聚体失调调节,导致谷氨酸能突触传递中断,与早期认知障碍平行。尽管人们普遍认为 AD 中的神经元死亡与细胞内 Ca(2+)(Ca(2+)(i))稳态紊乱有关,但对于包含 GluN2A 或 GluN2B 亚基的 NMDAR 在 Aβ 诱导的 Ca(2+)(i)升高和神经元功能障碍中的作用知之甚少。因此,这项工作的主要目标是评估 NMDAR 亚基在由 Aβ 1-42 制剂诱导的 Ca(2+)(i)稳态失调中的作用,该制剂包含较高比例的寡聚体(更多)和单体在大鼠皮质神经元中。通过使用 MK-801 或选择性 GluN2A 和 GLUN2B 亚基拮抗剂 NVP-AAM077 和ifenprodil 进行药理学抑制来评估 NMDAR 的参与。我们表明,Aβ 像 NMDA 一样,主要通过激活包含 GluN2B 亚基的 NMDAR 来增加 Ca(2+)(i)水平。相反,GluN2A-NMDAR 拮抗剂增强了由高浓度 Aβ(1μM)诱导的 Ca(2+)(i)升高,表明 GluN2A 和 GluN2B 亚基在调节 Ca(2+)(i)稳态方面具有相反的作用。此外,Aβ 调节 NMDA 诱导的反应,反之亦然。事实上,预先暴露于 Aβ(1μM)会降低 NMDA 诱发的 Ca(2+)(I)升高,而预先暴露于 NMDA 会降低 Aβ 的反应。有趣的是,同时添加 Aβ 和 NMDA 会增强 Ca(2+)(I)水平,这种效应以相反的方式受 GluN2A 和 GluN2B 亚基调节。这项研究通过探索 GluN2A 和 GluN2B 亚基在 AD 中 Aβ 毒性机制中的作用,有助于理解 AD 早期发病机制的分子基础。